Company:
Chronic kidney disease (CKD) is a serious and growing global health challenge, affecting approximately 1 in 7 people worldwide. In the absence of effective treatments, patients may progress to kidney failure, requiring dialysis or transplantation--placing a significant burden on patients, families, and healthcare systems. While recent advances have benefited certain subsets of kidney disease patients, many common forms of CKD still lack effective therapeutic options.
Borealis was founded on the belief that the convergence of scientific and translational breakthroughs can unlock the potential of RNA therapeutics to address some of the most rare and underserved kidney diseases--and beyond. Borealis builds on the success of Chinook Therapeutics, a kidney disease company with a research site in Vancouver that was acquired by Novartis in 2023 for $3.5 billion. The Borealis team has strong leadership and academic advisors with deep experience and expertise in both kidney disease and RNA therapeutics. Headquartered in Vancouver, BC, Borealis operates state-of-the-art wet labs equipped for molecular and cellular biology, in vivo pharmacology, chemistry, DMPK, bioinformatics, and analytical sciences.
We are a creative and innovative team that strives for excellence in all we do and have fun along the way. Our core focus is on helping patients and advancing science. For more information on Borealis, check out our sites https://borealisbio.com & https://www.linkedin.com/company/borealis-biosciences-inc.
MNCJobz.com will not be responsible for any payment made to a third-party. All Terms of Use are applicable.